Asia Executives On The Move: Sanofi's Global R&D Head Moves To Innovent
Executive Summary
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
You may also be interested in...
Interview: Janssen Builds Japan Specialty Interests But Wants Ongoing Policy Debate
Janssen’s Japan country president says while the company is committed to pursuing innovation, from a policy angle it would like to see this adequately rewarded, given the broader societal benefits it can bring. Amid increasing competition from the rest of Asia, the executive says Japan also has the chance to take a global research leadership position through appropriate reforms.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.